The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Myricx Bio Announces Series A Financing with Leading Life Science Investors
Jul 08, 2024•almost 2 years ago
Contract Type
partnership
LondonBiotechnologyHealth Care
Description
Myricx Bio has announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings and Abingworth. In connection with the financing, Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth will join Myricx’s Board of Directors. The funds will be used to build out Myricx’s proprietary N-Myristoyltransferase inhibitor (NMTi) ADC payload platform and to advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens.
Company Information
Company
Myricx Bio
Location
London, England, United Kingdom
About
Myricx Bio is a UK-based biotech company pioneering a completely new class of selective cytotoxic payloads for antibody drug conjugates (ADCs). Our approach is built on inhibitors of N-myristoyltransferases (NMT), targeting cancer with the potential to transform treatment outcomes.
LondonBiotechnologyHealth Care